All In Biotech

Drug Trial Radar · NCT00518713

Clobazam in Patients With Lennox-Gastaut Syndrome

Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome

Last checked: Nov 19, 2026Latest source record: Feb 9, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

238

Actual

Start

Aug 2007

Primary completion

Dec 2009

Study completion Apr 2010

Sponsor

Lead sponsor
Lundbeck LLCIndustry
Sponsor type
Industry
First posted
Aug 21, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in patients 2 to 60 years of age with Lennox-Gastaut Syndrome (LGS). Patients will be enrolled at approximately 65 sites in the U.S. and ex-US for up to 23 weeks. Patients will be randomly assigned to either a low, medium or high dose, or placebo. The study will include a baseline period, a titration period and a maintenance period. After the maintenance period, patients will either continue into an open-label extension study or enter the taper period with a final visit 1 week after the last dose.

Conditions

  • Epilepsy
  • Epilepsy, Generalized
  • Seizures

Interventions

  • Clobazam Low DoseDrug

    0.25 mg/kg/day; tablets; orally; for 15-18 weeks

  • Clobazam Medium DoseDrug

    0.5 mg/kg/day; tablets; orally; for 15-18 weeks

  • Clobazam High DoseDrug

    1.0 mg/kg/day; tablets; orally; for 15-18 weeks

  • PlaceboDrug

    tablets; orally; daily for 15-18 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Reduction in Number of Drop Seizures (12-week Maintenance Period).Time frame: 4-week baseline period and 12-week maintenance period

Locations

53 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Huntsville, Alabama

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Childrens Hospital Los Angeles

    Los Angeles, California

  • The Children's Hospital

    Aurora, Colorado

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Pediatric Neurology and Epilepsy Center

    Loxahatchee Groves, Florida

  • Child Neurology Center of NW FL

    Pensacola, Florida

  • University of South Florida

    Tampa, Florida

  • Pediatric Epilepsy & Neurology Specialists

    Tampa, Florida

  • Medical College of Georgia

    Augusta, Georgia

  • Pediatric Neurology of Idaho Children's Specialty Center

    Boise, Idaho

  • Rush University Medical Center

    Chicago, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • Children's Memorial Hospital

    Chicago, Illinois

  • University of Kentucky, Kentucky Clinic, Department of Neurology

    Lexington, Kentucky

  • LSU Health Sciences Center

    Shreveport, Louisiana

  • Mid-Atlantic Epilepsy and Sleep Center

    Bethesda, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Minnesota Epilepsy Group

    Saint Paul, Minnesota

  • The Comprehensive Epilepsy Care Center for Children and Adults

    Chesterfield, Missouri

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • Robert Wood Johnson University Hospital

    New Brunswick, New Jersey

  • St. Joseph's Regional Medical Center

    Paterson, New Jersey

  • Clinical Research Center of New Jersey (CRCNJ)

    Voorhees Township, New Jersey

  • University of Rochester Medical Center

    Rochester, New York

  • University Neurology, Inc.

    Cincinnati, Ohio

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Jefferson Epilepsy Center

    Philadelphia, Pennsylvania

  • UTMG Pediatric Neurology

    Memphis, Tennessee

  • Children's Medical Center at UT Southwestern-Dallas

    Dallas, Texas

  • Cook Children's Health Care System

    Fort Worth, Texas

  • Baylor College of Medicine Pediatric Neurology

    Houston, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • Strategic Health Evaluators

    Chatswood, New South Wales, Australia

  • Royal Melbourne Hospital Department of Neurology

    Melbourne, Victoria, Australia

  • Austin & Repatriation Hospital (Austin Health) Epilepsy Research Centre

    Melbourne, Victoria, Australia

  • Vitebsk Regional Diagnostic Center

    Vitebsk, Belarus

  • Neurology Center

    Ahmedabad, Gujarat, India

  • St. John's Medical College Hospital

    Bangalore, Karnataka, India

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.